Kaplan-Meier plots of event-free survival after relapse in all 111 relapsing patients. (A) All patients who carry TP53 and/or KRAS variants at initial diagnosis vs patients without such variants. (B) Patients in the standard-risk (SR) or medium-risk (MR) group who carry TP53 and/or KRAS variants at initial diagnosis vs SR/MR patients without such variants. (C) Patients in the HR group who carry TP53 and/or KRAS variants at initial diagnosis vs HR patients without such variants.